FN-1501

Generic Name: FN-1501

Brand Names: Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅N_₉O

CAS Number: 1429515-59-2

Unique Ingredient Identifier: 6MC966B505

Background: Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication: Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions: Transplanted Organ Rejection

Associated Therapies: -

Clinical Trials

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

Phase 2

Completed

Conditions: Antibody-mediated Rejection
Lung Transplant Rejection

Interventions: Drug: Tacrolimus
Drug: Belatacept
Drug: ATG
Drug: Mycophenolate Mofetil
Drug: Methylprednisolone
Drug: Prednisone

First Posted Date: 2018-01-02

Last Posted Date: 2022-11-25

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 27

Registration Number: NCT03388008

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

Phase 3

Active, not recruiting

Conditions: Pediatric Heart Transplantation
Immunosuppression
Chronic Kidney Diseases
Cardiac Allograft Vasculopathy
Heart Transplant Failure and Rejection
Post-transplant Lymphoproliferative Disorder
Heart Transplant Infection

Interventions: Drug: Everolimus
Drug: Tacrolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2017-12-29

Last Posted Date: 2023-10-17

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 211

Registration Number: NCT03386539

Locations: 🇺🇸
UCLA Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta Emory, Atlanta, Georgia, United States
🇺🇸
Lurie Children's Hospital, Chicago, Illinois, United States

and more 22 locations

Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects

Phase 4

Withdrawn

Conditions: Acute Cellular Graft Rejection
Liver Transplant Rejection

Interventions: Drug: Budesonide
Drug: Tacrolimus（FK506）
Drug: Mycophenolate Mofetil
Drug: Prednisone

First Posted Date: 2017-10-19

Last Posted Date: 2019-09-23

Lead Sponsor: Montefiore Medical Center

Registration Number: NCT03315052

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Phase 2

Conditions: Heart Transplantation

Interventions: Drug: Thymoglobulin
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Drug: Sirolimus
Drug: Corticosteroids

First Posted Date: 2017-09-26

Last Posted Date: 2024-12-16

Lead Sponsor: Cedars-Sinai Medical Center

Target Recruit Count: 60

Registration Number: NCT03292861

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

A Blood Stem Cell Transplant for Sickle Cell Disease

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease
Hemoglobinopathies
Thalassemia
Anemia, Sickle Cell
Sickle Cell Disorder

Interventions: Drug: Cyclophosphamide
Drug: Pentostatin
Drug: Rabbit anti-thymocyte globulin
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant

First Posted Date: 2017-08-15

Last Posted Date: 2024-03-07

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 3

Registration Number: NCT03249831

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Aggressive Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Plasma Cell Myeloma
Recurrent Small Lymphocytic Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2017-08-11

Last Posted Date: 2024-07-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT03246906

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine
Drug: Mycophenolate Mofetil
Drug: Sorafenib
Drug: Tacrolimus

First Posted Date: 2017-08-11

Last Posted Date: 2024-04-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT03247088

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis

Phase 2

Completed

Conditions: To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients

Interventions: Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil

First Posted Date: 2017-06-27

Last Posted Date: 2017-06-28

Lead Sponsor: Chitwan Medical College

Target Recruit Count: 49

Registration Number: NCT03200002

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia in Remission
Adult Acute Lymphoblastic Leukemia in Complete Remission
Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
Chronic Myelomonocytic Leukemia in Remission
Graft Versus Host Disease
Severe Aplastic Anemia
Hodgkin Lymphoma
Minimal Residual Disease
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan Hydrochloride
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-06-20

Last Posted Date: 2024-05-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 35

Registration Number: NCT03192397

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy

Phase 4

Conditions: Idiopathic Membranous Nephropathy

Interventions: Drug: Mycophenolate Mofetil
Drug: Cyclosporins

First Posted Date: 2017-05-31

Last Posted Date: 2019-03-18

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 128

Registration Number: NCT03170323

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy